| Current Price | $135.97 | Mkt Cap | $240.4B |
|---|---|---|---|
| Open | $135.50 | P/E Ratio | 32.22 |
| Prev. Close | $135.97 | Div. (Yield) | $5.64 (4.1%) |
| Daily Range | $135.36 - $138.30 | Volume | 212 |
| 52-Wk Range | $101.81 - $138.30 | Avg. Daily Vol. | 7,515,107 |
| Current Price | $135.97 | Mkt Cap | $240.4B |
|---|---|---|---|
| Open | $135.50 | P/E Ratio | 32.22 |
| Prev. Close | $135.97 | Div. (Yield) | $5.64 (4.1%) |
| Daily Range | $135.36 - $138.30 | Volume | 212 |
| 52-Wk Range | $101.81 - $138.30 | Avg. Daily Vol. | 7,515,107 |
The best Bull and Bear pitches based on recency and number of recommendations.
Good new drugs coming on line to replace the profits that came from Humira
This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For… More
Read the most recent pitches from players about ABBV.
Recs
JohnnyCaffeine
(< 20)
Submitted: 1/13/2022 6:48:34 AM :
Start Price:
$135.00
NYSE:ABBV Score:
+9.41
Good new drugs coming on line to replace the profits that came from Humira
Recs
TMFkodyk123
(57.65)
Submitted: 7/26/2021 12:53:49 PM :
Start Price:
$116.31
NYSE:ABBV Score:
+18.89
Despite AbbVie's near-term headwinds relating to the upcoming loss of exclusivity of Humira in the U.S., the company boasts promising drugs in its oncology and immunology segments. Venclexta has 3 different indications that are anticipated to be approved by next year. In addition, the stock appears to be trading at a discount to fair value with an attractive 4.4% dividend yield.
Recs
Millions2021
(< 20)
Submitted: 7/11/2021 6:45:46 PM :
Start Price:
$114.14
NYSE:ABBV Score:
+20.06
Great growth.
Find the members with the highest scoring picks in ABBV.
pirotta (< 20) Score: +290.58
The Score Leader is the player with the highest score across all their picks in ABBV.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| armydave | 61.77 |
|
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment | |
| pirotta | < 20 | 1/10/2013 |
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment | |
| deliman723 | 65.23 | 1/10/2013 |
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment | |
| concealedweaponR | < 20 | 1/10/2013 |
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment | |
| drjohn432 | < 20 |
|
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment | |
|
valari25 | 98.97 |
|
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment |
|
|
GW1000 | 84.89 |
|
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment |
|
|
mattmmurphy | 70.87 | 1/10/2013 |
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment |
| cooleyly | 53.20 | 1/10/2013 |
|
5Y | $23.26 | +484.57% | +194.00% | +290.58 | 0 Comment | |
|
|
kinosternon | 97.63 | 1/9/2013 |
|
5Y | $23.37 | +481.92% | +195.35% | +286.56 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
